{
    "id": "35d13593-172f-3a08-e063-6294a90a72fe",
    "indications": {
        "text": "valproic acid anti-epileptic indicated : monotherapy adjunctive therapy complex partial seizures ; sole adjunctive therapy simple complex absence seizures ; adjunctive therapy patients multiple seizure types include absence seizures ( 1 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "valproic acid intended oral . ( 2.1 ) simple complex absence seizures : start 10 15 mg/kg/day , increasing 1 week intervals 5 10 mg/kg/week seizure control limiting side effects ( 2.1 ) safety doses 60 mg/kg/day established ( 2.1 , 2.2 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "valproic acid capsules , usp , 250 mg. off-white colored soft gelatin capsule imprinted valproic 250 made available bottles 100 capsules ( ndc0591-4012-01 ) . store capsules controlled room temperature 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) , usp . dispense tight , light-resistant container .",
    "adverseReactions": "valproic acid administered patients hepatic disease significant hepatic dysfunction [ ( 5.1 ) ] . valproic acid contraindicated patients known mitochondrial disorders caused mutations mitochondrial dna polymerase \u03b3 ( polg ; e.g . , alpers-huttenlocher syndrome ) children two years age suspected polg-related disorder [ ( 5.1 ) ] . valproic acid contraindicated patients known hypersensitivity [ ( 5.12 ) ] . valproic acid contraindicated patients known urea cycle disorders [ ( 5.6 ) ] . prophylaxis migraine headaches : valproic acid contraindicated women pregnant women childbearing potential using effective contraception [ warning ( 5.2 , 5.3 , 5.4 ) ( 8.1 ) ] .",
    "ingredients": [
        {
            "name": "PEANUT OIL",
            "code": "5TL50QU0W4",
            "drugbank_id": "https://go.drugbank.com/drugs/DB13964"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX",
            "drugbank_id": "https://go.drugbank.com/drugs/DB09462"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "VALPROIC ACID",
            "code": "614OI1Z5WI",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_39867"
        }
    ],
    "organization": "Aphena Pharma Solutions - Tennessee, LLC",
    "name": "Valproic",
    "effectiveTime": "20250523",
    "indications_original": "Valproic Acid is an anti-epileptic drug indicated for: Monotherapy and adjunctive therapy of complex partial seizures; sole and adjunctive therapy of\u00a0simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types\u00a0that include absence seizures ( 1 )",
    "contraindications_original": "Valproic Acid is intended for oral administration. ( 2.1 ) Simple and Complex Absence Seizures: Start at 10 to 15 mg/kg/day, increasing at 1 week intervals by 5 to 10 mg/kg/week until seizure control or limiting side effects ( 2.1 ) Safety of doses above 60 mg/kg/day is not established ( 2.1 , 2.2 )",
    "warningsAndPrecautions_original": "Valproic Acid Capsules, USP, 250 mg. Each off-white colored soft gelatin capsule is imprinted with VALPROIC 250 and made available in bottles of 100 capsules (\n \n  NDC0591-4012-01).\n\n \n                  Store capsules at controlled room temperature 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F), see USP.\u00a0Dispense in tight, light-resistant container.",
    "adverseReactions_original": "Valproic Acid should not be administered to patients with hepatic disease or significant hepatic dysfunction\n  \n   [\n                        see Warnings and Precautions (\n                        \n                           5.1\n                        \n                        )\n                        ]. \n   \n                     \n                     Valproic Acid is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase \u03b3 (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder\n  \n   [\n                        see Warnings and Precautions (\n                        \n                           5.1\n                        \n                        )\n                        ].\u00a0 \n   \n                     \n                     Valproic Acid is contraindicated in patients with known hypersensitivity to the drug\n  \n   [\n                        see Warnings and Precautions (\n                        \n                           5.12\n                        \n                        )\n                        ]. \n   \n                     \n                     Valproic Acid is contraindicated in patients with known urea cycle disorders\n  \n   [\n                        see Warnings and Precautions (\n                        \n                           5.6\n                        \n                        )\n                        ].\n                     \n                     For use in prophylaxis of migraine headaches: Valproic Acid is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception\n  \n   \n                           \n                              \n                                 \n                                    [see Warning and Precautions (\n       \n        5.2,\n       \n        5.3,\n       \n        5.4) and Use in Specific Populations (\n       \n        8.1)].",
    "drug": [
        {
            "name": "Valproic",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00313"
        }
    ]
}